Claims

1. The use of MAP as an active ingredient in the manufacture of a composition for the treatment of inflammation of the mucosa.

2. The use according to claim 1, wherein the MAP comprises one or more of the sub-types selected from the group: mefp-1, mefp-2, mefp-3, mefp-4, mefp-5, mefp-6, the collagens pre-COL-P, pre-COL-D, pre-COL-NG, and the mussel feet matrix proteins PTMP, and DTMP.

3. The use according to claim 2, wherein the MAP comprises one or more of the sub-types selected from the group mefp-1, mefp-2, mefp-3, mefp-4, mefp-5 and mefp-6.

4. The use according to claim 3, wherein the MAP comprises mefp-1.

5. The use according to any one of claims 1-4, wherein the MAP concentration is 0.1-15.0 mg/mL.

6. The use according to any one of claims 1-5, wherein the composition is a liquid formulation, a gel formulation or a foam formulation.

7. The use according to any one of claims 1-6, wherein MAP in the final product is in a range of pH 1.0-7.0, and in particular, in a range of pH 3.0-6.5.

8. The use of MAP according to any one of claims 1-7, wherein the inflammation of the mucosa is selected from: oral mucositis, rhinitis, otitis media, conjunctivitis, pharyngitis, laryngitis, tracheitis, esophagitis, gastritis, enterocolitis, cervicitis, endometritis, an inflammation caused by inhalation injury, and the like.

9. The use of MAP according to any one of claims 1-7, wherein the MAP treats a cancer selected from: an oral cancer, a nasopharynx cancer, a middle ear cancer, a conjunctival cancer, a throat cancer, a tracheal cancer, an esophageal cancer, a gastric cancer, an intestinal cancer, a cervical cancer, an endometrial cancer, and the like, caused by one or more of oral mucositis, rhinitis, otitis media, conjunctivitis, pharyngitis, laryngitis, tracheitis, esophagitis, gastritis, enterocolitis, cervicitis, endometritis, and the like.

10. The use according to any one of claims 1-9, wherein the composition is used by means of oral administration, sublingual administration, perfusion, is in the form of eye drops, a nasal spray, an oral spray, a cavity scope, a directional local sustained release formulation, or by means of targeted administration.

11. The use of MAP according to any one of claims 1-10 wherein the composition is a medicament, a cosmetic, a disinfecting product, a healthcare product, a food or a household chemical.